| | Webinar: 2021 Apollo Healthcare Predictions Thursday, February 4, 2021 | 1pm ET / 10am PT With so much disruption from COVID-19, this year’s global insights will provide a unique window into the minds of those professionals perhaps most tested by 2020 and their hopes and perspectives for 2021. Register Now! |
Biden pledges to boost vaccine confidence—but how? Ad agency execs weigh in Novavax sees some COVID-19 vaccine trial dropout as Pfizer, Moderna rollouts gear up Zocdoc, Notable Health roll out tools to help automate COVID-19 vaccine screenings and scheduling Ride Health gives patients a lift to COVID-19 treatment, vaccine trials Biden and biotech: Science first While pandemic takes top priority for Biden, experts see favorable landscape for drug pricing action in Washington In vitro test maker Ortho Clinical Diagnostics files $1.5B Nasdaq IPO Healthcare roundup: WellCare launches home testing pilot for MA members Biopharma roundup: Ontario presses U.S. for extra Pfizer doses as Italy threatens to sue over vaccine delivery delays UnitedHealthcare expects to add 900K Medicare members this year GlaxoSmithKline PD-1 hopeful dostarlimab fell victim to COVID-related inspection delay Featured Story | By Beth Snyder Bulik As President Joseph Biden takes office today, organizing vaccine distribution and increasing vaccine supplies are day one priorities. But a bigger challenge to stemming the pandemic is much less concrete. How do you get people to believe? read more |
| |
|---|
|
Top Stories By Angus Liu As supplies of Pfizer-BioNTech and Moderna’s authorized COVID-19 vaccines make their way around the country, many states are expanding beyond the 75-plus age group to reach people 10 years younger. That broader rollout has older people asking to drop out of Novavax's phase 3 vaccine trial. read more By Brian T. Horowitz As states struggle to ramp up distribution of COVID-19 vaccines and match supply with demand, intelligent automation software company Notable Health recently announced it has upgraded its platform to help automate COVID-19 vaccine administration workflows and screen for eligibility. read more By Amirah Al Idrus Access to private transportation, or lack thereof, has long been a barrier to participation in clinical trials. And COVID-19 isn’t making things easier, with public health guidelines discouraging the use of public transport and ride-hailing services setting up policies against passengers with COVID-19 symptoms. read more By Ben Adams The November election now seems such a long time ago: It has, in fact, been less than three months, but that time has been filled with political and scientific catastrophes that will shape President Joe Biden’s term in office. read more By Eric Sagonowsky While the COVID-19 pandemic will be the “first, second and third” priority for the Biden administration, as one expert put it, expect some drug pricing action down the road. Aggressive measures such as Medicare price negotiations still might falter in Congress. But there's some "low-hanging fruit" lawmakers could tackle first. read more By Conor Hale Ortho Clinical Diagnostics is hoping to ride a wave of COVID-19 and broader in vitro lab testing to a $1.5 billion IPO. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale Canada pressed the U.S. for extra doses of Pfizer's shot. Meanwhile, Italy says it plans to sue Pfizer over delayed vaccine deliveries. Ad agency execs weighed in on ways President Biden can boost vaccine confidence. Ride Health is looking to help get people to and from COVID-19 trials. Plus, India started exporting AstraZeneca vaccine doses. read more By Paige Minemyer UnitedHealth Group reported $2.2 billion in profit for the fourth quarter of 2020, bringing its full-year earnings to $15.4 billion. read more By Fraiser Kansteiner The COVID-19 pandemic was responsible for a slew of drug approval delays last year, and GlaxoSmithKline's PD-1 hopeful dostarlimab was not immune, the company has revealed. Pandemic travel restrictions kept an FDA manufacturing inspection from occurring, causing GSK to revise its approval timeline for the first half of 2021. read more |
